Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by Gbathaton Feb 01, 2020 7:16pm
134 Views
Post# 30629924

January 2020 presentation looks great

January 2020 presentation looks greathttps://promisneurosciences.com/wp-content/uploads/2020/01/Corporate-Overview-deckJan24_2020.pdf

T
he data shown in this presentation are compelling, well controlled, and well organized.  And the microscopy is beautiful.  As someone who worked on protein binding assays during my doctoral studies, I know this work is not easy, and I was working with much simpler systems.

These diseases have taken life and quality of life from so many, as I have witnessed with close friends, family, and mentors.  AZ, Parkinsons, and ALS are diagnoses that should be rightfully feared.  PMN offers hope, in addition to the ROI opportunities mentioned in my previous post.  Even if someone beats us to the punch, that is a good outcome for us all, when considering the bigger picture.

I believe the future is bright.  
Bullboard Posts